Release Testing

GMP release testing aligned with approved specifications for confident batch release.

Release testing-1

Confident batch release testing

Testing spans raw materials, packaging components, and finished products in support of batch release.

Groupe PARIMA performs release testing starting with raw materials and packaging components. Incoming testing confirms identity and quality attributes to support material use and reliable downstream processing.

Finished product release is supported by physicochemical and microbiological testing conducted in our internal GMP laboratories using validated or qualified methods aligned with approved specifications.

Release activities

Release testing activities span materials, components, finished products, and stability to support batches across development and commercial stages.

api and excipients testing (2) - Copy

API and excipients testing

Active pharmaceutical ingredients and excipients are tested to confirm identity and critical quality attributes prior to use in manufacturing.

packaging components

Packaging components

Primary packaging components are evaluated to confirm identity and defined attributes relevant to product protection and compatibility.

finished drug products

Finished drug products

Finished products are tested using physicochemical and microbiologically validated methods aligned with release specifications.

Stablity testing for shelf life

stability testing for shelf life

Stability testing supports release and shelf‑life claims by monitoring product attributes and trends over defined storage conditions.

Chemistry Testing Capabilities

Our in-house equipment supports stage-appropriate method development and routine testing across chromatography, particle sizing, physical testing, and dissolution.

01
potency determination

Potency determination

Quantitative analysis to confirm active ingredient concentration and ensure therapeutic efficacy.

02
FTIR identification

FTIR identification

Fourier-transform infrared spectroscopy for rapid and reliable compound identification.

03
impurity profiling

Impurity profiling 

Detection and quantification of impurities and degradation products to support product safety and shelf-life evaluation.

04
Residual solvent analysis

Residual solvent analysis

Ensures residual solvents are within safe, regulatory-approved limits, supporting compliance and patient safety.

05
Dissolution Performance

Dissolution performance 

Evaluates drug release profiles to predict bioavailability and support product performance claims.

06
Analytical testing

Analytical testing

Analytical testing includes viscosity, pH, moisture, particle and droplet size, density, and deliverable volume to support formulation performance.

Release testing at Groupe PARIMA supports predictable batch disposition through controlled, specification‑driven testing.

Microbiology Testing Capabilities

Comprehensive microbiology testing to support product safety, quality control, and compliance with USP and EP requirements.

01
Aerobic Microbial enumeration -

Aerobic Microbial Enumeration

Measure aerobic bacteria using validated method in accordance with USP <61> and EP 2.6.12 to assess overall microbial load.

02
aerobic microbial enumeration

Fungal Microbial Enumeration

Quantify yeast and mold levels using a validated analytical method in accordance with USP <61> and EP 2.6.12 to ensure product safety.

03
fungal microbial enomeration

Microbial Suitability Testing

Screen for objectionable microorganisms as defined in USP <62>, USP <60>, and EP 2.6.13, based on dosage form and intended use.

04
Microbial suitability testing

Microbial Identification Testing

Identify microbial isolates to support contamination investigations and corrective actions.

05
microbial identification testing

Preservative Efficacy Testing

Confirm preservative system efficacy in multi-dose products in accordance with USP <51>.

Resources

Access technical insights and guidance to support informed decisions around release testing and analytical strategy.

White papers
2026/07/06
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
White papers
2026/07/03
How Early API Characterization Can Reduce Formulation and Scale-up Risks
White papers
2026/07/06
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
White papers
2026/07/03
How Early API Characterization Can Reduce Formulation and Scale-up Risks

Contact Us

Discuss your project needs

Connect with our team to review your release testing needs across materials, packaging components, and finished products.